2019 Publications of Interest
C-NPU: Nomenclature, Properties and Units - Joint Committee of IFCC/IUPAC
Young Bae Lee Hansen: Recommendations on measurement units – why and how: eJIFCC Volume 30 no 3 – 2019
C-MD: Molecular Diagnostics Committee
External Quality Assessment (EQA) and Alternative Assessment Procedures (AAP) in Molecular Diagnostics: Findings of an International Survey. Deborah A. Payne, Graciela Russomando, Mark W. Linder, Katarina Baluchova, Tester Ashavaid, Werner Steimer, Parviz Ahmad-Nejad, and the IFCC Committee for Molecular Diagnostics (C-MD) Approved by the SD. Now in submission process; probably CCA
C-TLM: Traceability in Laboratory Medicine
The results of RELA2018 have been evaluated and published http://www.dgkl-rfb.de:81
C-BM: Bone Metabolism
1. “A multicenter assay to evaluate the harmonization of PINP assays: a report of the IOF IFCC Committee on Bone metabolism” accepted for publication in CCLM;
2. Abstract on “PINP harmonization: a report of the IOF-IFCC Committee for Bone metabolism” presented during IOF meeting in Paris on April 5th
WG-SAU: Standardization of Albumin Assay in Urine – in collaboration with NKDEP
Miller WG, Bachmann LM, Fleming JK, Delanghe JR, Parsa A, Narva AS. Recommendations for reporting low and high values for urinary albumin and total protein [Letter to the Editor]. Clin Chem 2019; 65(2):349-350.
WG-APO MS: Apolipoproteins by Mass Spectrometry
The group aims for submission of the following manuscripts in 2020:
- A first manuscript will be a conceptual paper on standardization of multiple apolipoproteins with a common LC-MS approach, and will cover the clinical rationale and the unmet clinical needs for personalized and stratified cardiovascular risk assessment and treatment as well as the metrological striving for establishing SI-traceable multiplex apo test.
- By invitation: a special paper on apo(a) standardization will be written for the special issue of CCA.
- A third manuscript will be a technical note or letter on the improved digestion of apolipoproteins using a combination of lysC and trypsin. This manuscript will summarize the findings and evidence gathered by the three reference labs (LUMC, CDC and UKL).
- A fourth manuscript that will be in the preparation phase by the end of 2020 is the development of a harmonized LC-MS based reference method, including results from the planned ring trials.
Members of the group have participated in several related publications:
• Orsi FA, Lijfering WM, Van der Laarse A, Ruhaak LR, Rosendaal FR, Cannegieter SC, Cobbaert C. Association of apolipoproteins C-I, C-II, C-III and E with coagulation markers and venous thromboembolism risk. Clin Epidemiol. 2019 https://doi.org/ 10.2147/CLEP.S196266.
• Ruhaak LR, Van der Laarse A, Cobbaert CM. Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. Annals of Clinical Biochemistry. 2019 https://doi.org/10.1177/0004563219827620
• Dittrich J, Beutner F, Teren A, Thiery J, Burkhardt R, Scholz M, Ceglarek U. Plasma levels of apolipoproteins C-III, A-IV, and E are independently associated with stable atherosclerotic cardiovascular disease. Atherosclerosis. 2019 Feb;281:17-24. https://doi.org/10.1016/j. atherosclerosis.2018.11.006
WG-cfDNA: Cell free DNA and related circulating biomarkers
What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? - Practical recommendations on pre-analytical issues by the IFCC workgroup cfDNA R. Danesi, Y. M. D. Lo, M. Oellerich, J. Beck, S. Galbiati, M. del Re, E. Lianidou, M. Neumaier, R.H.N. van Schaik – On behalf of the IFCC Working Group cfDNA (to be submitted to CCA)